SCHEMBL28552109

SCHEMBL28552109

CC(C)(C)C(OC(N)=O)c1ccc(NS(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PTPN11 Q06124 1/20 0.49
PTPN1 P18031 1/20 0.47
CA2 P00918 7/20 0.46
CA1 P00915 4/20 0.42
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
HSPD1 P10809 1/20 0.36
HSPE1 P61604 1/20 0.36
PPARA Q07869 4/20 0.36
PPARG P37231 1/20 0.36
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966433 0.76 MAPK1 (0.56) MAPK1SMN1; SMN2PTPN11PTPN1CA2
SCHEMBL5026454 0.74 PARP10 (0.34) MAPK1SMN1; SMN2CYP3A4SLC6A3EPHX2
SCHEMBL28601844 0.73 LOXL2 (0.41) SMN1; SMN2
SCHEMBL31348907 0.72 ALOX5 (0.44) SMN1; SMN2CYP2D6
SCHEMBL7208755 0.72 PTPN11 (0.61) MAPK1SMN1; SMN2PTPN11PTPN1CA2
SCHEMBL1345154 0.72 MAPK1 (0.58) MAPK1SMN1; SMN2PTPN11PTPN1CA2
SCHEMBL1344975 0.72 MAPK1 (0.58) MAPK1SMN1; SMN2PTPN11PTPN1CA2
SCHEMBL29156721 0.71 NPSR1 (0.47) MAPK1CA2CA1
SCHEMBL3378865 0.70 SMN1; SMN2 (0.60) MAPK1SMN1; SMN2PTPN11PTPN1CA2
SCHEMBL8864779 0.69 MAPK1 (0.51) MAPK1SMN1; SMN2PTPN11PTPN1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106573899-B Optionally fused, heterocyclyl-substituted pyrimidine derivatives for the treatment of inflammatory, metabolic, neoplastic and autoimmune diseases 纽韦卢森公司 2021-04-06 CN disclosed